Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice

Objective: to assess bone mineral density (BMD) changes in rheumatoid arthritis (RA) patients with osteoporosis (OP) and in women with postmenopausal OP during therapy with denosumab (DSB) for 1 year

Subjects and methods. 121 women were included: the main group – 69 patients with RA (mean age – 60±7 years), 34 (49.3%) from them received glucocorticoids (GC). Comparison group comprised 52 women with primary OP (mean age – 62±10 years). Measurement of BMD using dual-energy X-ray absorptiometry (DXA) was performed in the lumbar spine (L_I–IV), femoral neck (FN), proximal femur as a whole (PF) and distal forearm (DF). DSB was administered subcutaneously at a dose of 60 mg 1 time in 6 months.

Results and discussion. In patients with RA, the average increase of BMD for 12 months of treatment was: in L_I–IV – 4.6%, in FN-2.8%, in PF-3.0% and in DF-0.7%, and in the comparison group – 5.2; 2.1; 2.9 and 0.9%, respectively. There were no significant differences of BMD changes between the groups. Efficacy of DSB therapy in RA patients with OP did not depend on RA activity, duration of GC therapy and cumulative dose of GC. Adverse events that did not lead to the withdrawal of the drug were noted in 3% of the study participants. There were no fractures during the observation.

Conclusion. The efficacy treatment with DSB for 1 year in RA patients with OP and in women with postmenopausal OP is comparable. The use of GC did not have a negative impact on DSB effect.

1. Straub RH. Interaction of the endocrine system with inflammation: a function of energy and volume regulation. Arthritis Res Ther. 2014;16(1):203. doi: 10.1186/ar4484

2. Rossiiskii statisticheskii ezhegodnik [Russian statistical yearbook]. Moscow: Rosstat; 2017. 686 p. (In Russ.)

3. Nikitinskaya OA, Toroptsova NV, Demin NV, et al. The risk of osteoporotic fractures in patients with rheumatoid arthritis: results of the program «Osteoscreening Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):310-5 (In Russ.). doi: 10.14412/1995-4484-2018-310-315

4. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis. 2000;59(2):110-5. doi: 10.1136/ard.59.2.110

5. Kvien TK, Haugeberg G, Uhlig T, et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. Ann Rheum Dis. 2000;59(10):805-11. doi: 10.1136/ard.59.10.805

6. Taskina EA, Alekseeva LI, Dydykina IS, et al. Risk factors for osteoporosis in patients with rheumatoid arthritis (preliminary results according to the materials of the multicenter program «Osteoporosis in rheumatoid arthritis: Diagnosis, risk factors, fractures, treatment»). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):393-7 (In Russ.). doi: 10.14412/1995-4484-2014-393-397

7. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management of steroid-induced osteoporosis. J Bone Miner Res. 1999;14:1061.

8. Wijbrandts СА, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68(3):373-6. doi: 10.1136/ard.2008.091611

9. Baranova IA, Ershova OB, Anaev EKh, et al. Assessment of the frequency and risk factors for low-energy skeletal fractures according to a survey of patients with chronic inflammatory diseases. The results of a multicenter study of the Russian Association for Osteoporosis GLUCOST. Osteoporoz i Osteopatii. 2014;(3):9-14 (In Russ.)

10. Toroptsova NV, Nikitinskaya OA. Adherence to osteoporosis treatment in patients with rheumatoid arthritis. Russkii Meditsinskii Zhurnal. 2014;(7):491-4 (In Russ.)

11. Kearns АЕ , Khosla S, Kostenuik P. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine Rev. 2008;29(2):155-92. doi: 10.1210/er.2007-0014

12. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23. doi: 10.1016/S2213-8587(17)30138-9

13. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a 12-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299-309. doi: 10.1002/art.23417

14. Takeuchi T, Tanaka Y,Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE) – a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75(6):983-90. doi: 10.1136/annrheumdis-2015-208052

15. Mochizuki T, Yano K, Ikari K, et al. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis. J Bone Miner Metab. 2018;36(4):431-8. doi: 10.1007/s00774-017-0848-1

16. Suzuki T, Nakamura Y, Kato H. Determination of serum bonerelated minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis: Mineral change by denosumab in osteoporosis with rheumatoid arthritis. Clin Nutr ESPEN. 2018;26:53-6. doi: 10.1016/j.clnesp.2018.04.014

17. Ebina K, Hirao M, Hashimoto J, et al. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab. 2018;36(4):478-87. doi: 10.1007/s00774-017-0861-4

18. Banshchikova NE, Letyagina EA, Omel'chenko VO, Korolev MA. Anti-resorptive activity of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis. Osteoporoz i Osteopatii. 2018;21(2):4-1 (In Russ.). doi: 10.14341/osteo9826

19. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479-89. doi: 10.1007/s00198-015-3164-4

20. Hadji PKS, Häussler B, Kless T, et al. The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther. 2013;51:868-72. doi: 10.5414/CP201931

21. Lau AN, Wong-Pack M, Rodjanapiches R, et al. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting. J Rheumatol. 2018;45(2):170-6. doi: 10.3899/jrheum.161270

22. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445-54. doi: 10.1016/S2213-8587(18)30075-5